Table 2.
SARS-CoV-2 neutralizing antibody and T cell response.
| Assay | All patients (n = 88) | KTRs | Prior infection | ||||
|---|---|---|---|---|---|---|---|
| No (n = 69) | Yes (n = 19) | P value | No (n = 59) | Yes (n = 29) | P valuea | ||
| NAb detected | |||||||
| Ancestral | 62 (70.5) | 51 (73.9) | 11 (57.9) | 0.255 | 39 (66.1) | 23 (79.3) | 0.226 |
| BA.2.2 | 52 (59.1) | 42 (60.9) | 10 (52.6) | 0.602 | 25 (42.4) | 27 (93.1) | < 0.001 |
| BA.2.3.20 | 41 (46.6) | 32 (46.4) | 9 (47.4) | 1.000 | 19 (32.2) | 22 (75.9) | < 0.001 |
| BA.5.2 | 37 (42) | 28 (40.6) | 9 (47.4) | 0.610 | 17 (28.8) | 20 (69.0) | 0.001 |
| XBB.1 | 23 (26.1) | 18 (26.1) | 5 (26.3) | 1.000 | 8 (13.6) | 15 (51.7) | < 0.001 |
| IGRA positive | 52 (59.1) | 42 (60.9) | 10 (52.6) | 0.602 | 31 (52.5) | 21 (72.4) | 0.106 |
| nAb not detectedb & IGRA negative | 14 (15.9) | 7 (10.1) | 7 (36.8) | 0.010 | 13 (22.0) | 1 (3.4) | 0.030 |
Data are n (%).
Abbreviations: IGRA, interferon gamma release assay; nAb, neutralizing antibody.
aFisher’s exact test.
bNeutralizing antibody not detected against ancestral strain, BA.2.2, BA.2.3.20, BA.5.2 and XBB.1.